![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Jackisch, Christian; Barcenas, Carlos H.; Bartsch, Rupert; Di Palma, Jack; Glueck, Stefan; Harbeck, Nadia; Macedo, Guilherme; O'Shaughnessy, Joyce; Pistilli, Barbara; Ruiz-Borrego, Manuel und Rugo, Hope S.
(2021):
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
In: Clinical Breast Cancer, Bd. 21, Nr. 5, E575-E583
O'Shaughnessy, Joyce; Schwartzberg, Lee; Piccart, Martine; Rugo, Hope S.; Yardley, Denise A.; Cortes, Javier; Untch, Michael; Harbeck, Nadia; Wright, Gail S.; Bondarenko, Igor; Glaspy, John; Nowecki, Zbigniew; Kayali, Fadi; Chan, Arlene; Levy, Christelle; Liu, Mei-Ching; Kim, Sung-Bae; Lemieux, Julie; Manikhas, Alexey; Tolaney, Sara; Lim, Elaine; Gombos, Andrea; Stradella, Agostina; Pegram, Mark; Fasching, Peter; Mangel, Laszlo; Semiglazov, Vladimir; Dieras, Veronique; Gianni, Luca; Danso, Michael A.; Vacirca, Jeff; Kroll, Stew; O'Connell, Joseph; Tang, Kevin; Wei, Thomas und Seidman, Andrew
(2021):
Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane.
In: Clinical Advances in Hematology & Oncology, Bd. 19, Nr. 2: S. 12-13
Schmid, Peter; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Fasching, Peter A.; Cardoso, Fatima; Untch, Michael; Jia, Liyi; Karantza, Vassiliki; Zhao, Jing; Aktan, Gursel; Dent, Rebecca und O'Shaughnessy, Joyce
(2020):
Pembrolizumab for Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 382, Nr. 9: S. 810-821
Johnston, Stephen R. D.; Harbeck, Nadia; Hegg, Roberto; Toi, Masakazu; Martin, Miguel; Shao, Zhi Min; Zhang, Qing Yuan; Martinez Rodriguez, Jorge Luis; Campone, Mario; Hamilton, Erika; Sohn, Joohyuk; Guarneri, Valentina; Okada, Morihito; Boyle, Frances; Neven, Patrick; Cortes, Javier; Huober, Jens; Wardley, Andrew; Tolaney, Sara M.; Cicin, Irfan; Smith, Ian C.; Frenzel, Martin; Headley, Desiree; Wei, Ran; San Antonio, Belen; Hulstijn, Maarten; Cox, Joanne; O'Shaughnessy, Joyce und Rastogi, Priya
(2020):
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
In: Journal of Clinical Oncology, Bd. 38, Nr. 34
Yardley, Denise A.; Brufsky, Adam; Coleman, Robert E.; Conte, Pierfranco F.; Cortes, Javier; Glück, Stefan; Nabholtz, Jean-Mark A.; O'Shaughnessy, Joyce; Beck, Robert M.; Ko, Amy; Renschler, Markus F.; Barton, Debora und Harbeck, Nadia
(2016):
Erratum to: Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015).
In: Trials
17
[PDF, 357kB]
Yardley, Denise A.; Brufsky, Adam; Coleman, Robert E.; Conte, Pierfranco F.; Cortes, Javier; Glueck, Stefan; Nabholtz, Jean-Mark A.; O'Shaughnessy, Joyce; Beck, Robert M.; Ko, Amy; Renschler, Markus F.; Barton, Debora und Harbeck, Nadia
(2015):
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
In: Trials
16:575
[PDF, 1MB]